Two galantamine titration regimens in patients switched from donepezil

Acta Neurologica Scandinavica

Volumn 126, Issue 1, 2012, Pages 37-44

  Engedal, K ^a   Davis, B ^b   Richarz, U ^c   Han, J ^d   Schauble B ^e   Andreasen, N ^f  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Synaptec Inc   (United States)

^c GMAL Established Products   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e JANSSEN CILAG GMBH   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Donepezil; Drug switching; Galantamine; Randomized controlled trial

Indexed keywords

ANTIEMETIC AGENT; DIURETIC AGENT; DONEPEZIL; GALANTAMINE; PROPANTHELINE BROMIDE;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ARTICLE; BRADYCARDIA; CEREBROVASCULAR DISEASE; CONFUSION; CONTROLLED STUDY; CYSTITIS; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPESTHESIA; MAJOR CLINICAL STUDY; MALAISE; MINI MENTAL STATE EXAMINATION; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SPEECH DISORDER; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 84861922250     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01594.x     Document Type: Article

References (46)

1. NICE. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London: National Institute for Health and Clinical Excellence, 2007.
2. Deutsche Gesellschaft für Psychiatrie Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN). S3-Leitlinie 'Demenzen'. 2009; (last accessed 18 April 2011).
3. Socialstyrelsen. Nationella riktlinjer för vård och omsorg vid demenssjukdom 2010 - stöd för styrning och ledning. Västerås: Edita Västra Aros, 2010.
4. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias, 2nd edn. Arlington, VA: American Psychiatric Publishing, Inc., 2007.
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;25(1):CD005593.
6. Gardette V, Andrieu S, Lapeyre-Mestre M et al.Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs 2010;24:431-42.
7. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005;11:231-51.
8. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging 2005;22:695-707.
9. Starner CI, Gleason PP. Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts. J Manag Care Pharm 2008;14:462-4.
10. Gauthier S, Emre M, Farlow MR et al.Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003;19:707-14.
11. Bartorelli L, Giraldi C, Saccardo M et al.Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005;21:1809-18.
12. Edwards K, Therriault OJ, Gorman C. Switching from donepezil or rivastigmine to galantamine in clinical practice. J Am Geriatr Soc 2004;52:1965.
13. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl 2002;127:64-72.
14. Samochocki M, Hoffle A, Fehrenbacher A et al.Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-36.
15. Nordberg A, Darreh-Shori T, Peskind E et al.Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:4-14.
16. Vemuri P, Wiste HJ, Weigand SD et al.MRI and CSF biomarkers in normal, MCI and AD subjects. Predicting future clinical change. Neurology 2009;73:294-301.
17. Parnetti L, Chiasserini D, Andreasson U et al.Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Acta Neurol Scand 2011;124:122-9.
18. Wilkinson DG, Howe I. Switching from donepezil to galantamine: a double-blind study of two wash-out periods. Int J Geriatr Psychiatry 2005;20:489-91.
19. Ferris SH. Switching previous therapies for Alzheimer's disease to galantamine. Clin Ther 2001;23(Suppl. A):A3-7.
20. McKhann G, Drachman D, Folstein M et al.Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
21. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19:448-50.
22. Wiig EH, Annas P, Basun H et al.The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurol Scand 2010;121:186-93.
23. Schneider LS, Olin JT, Doody RS et al.Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl. 2):S22-32.
24. Galasko D, Bennett D, Sano M et al.An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl. 2):S33-9.
25. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
26. Sadowsky CH, Dengiz A, Meng X, Olin JT. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. Prim Care Companion J Clin Psychiatry 2010;12:pii:PCC.09m00852.
27. Stern RG, Mohs RC, Davidson M et al.A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-6.
28. Maelicke A. Pharmacokinetic rationale for switching from donepezil to galantamine. Clin Ther 2001;23(Suppl. A):A8-12.
29. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
30. Burns A, Rossor M, Hecker J et al.The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10: 237-44.
31. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:806-12.
32. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33.
33. Shigeta M, Homma A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001;7:353-68.
34. Holmes C, Wilkinson D, Dean C et al.The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-9.
35. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-44.
36. Johannsen P, Salmon E, Hampel H et al.Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs 2006;20:311-25.
37. Garcia-Ayllón MS, Silveyra MX, Saez-Valero J. Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid. Chem Biol Interact 2008;175:209-15.
38. Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today (Barc) 2003;39:75-83.
39. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur J Biochem 1999;264:672-86.
40. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull 2009;32:332-6.
41. Kuryatov A, Onksen J, Lindstrom J. Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol 2008;74:132-43.
42. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
43. Tariot PN, Solomon PR, Morris JC et al.A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
44. Brodaty H, Corey-Bloom J, Potocnik FC et al.Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120-32.
45. Erkinjuntti T, Kurz A, Gauthier S et al.Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90.
46. Zhao Q, Janssens L, Verhaeghe T, Brashear HR, Truyen L. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005;21:1547-54.